Search Results

Display Settings
Results per page: 10
Sort By: Relevance
Filter
  • 1-10 of  623 results for ""Xenograft Model Antitumor Assays""

Your Filters

Publisher : oxford university press
Reset filters
Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request
Academic Journal

Targeting HTR2B suppresses nonfunctioning pituitary adenoma growth and sensitizes cabergoline treatment via inhibiting Gαq/PLC/PKCγ/STAT3 axis.

  • Authors : Lin S; Department of Neurosurgery, Center of Pituitary Tumor, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.; Wang L

Subjects: Pituitary Neoplasms*/Pituitary Neoplasms*/Pituitary Neoplasms*/drug therapy ; Pituitary Neoplasms*/Pituitary Neoplasms*/Pituitary Neoplasms*/pathology ; Pituitary Neoplasms*/Pituitary Neoplasms*/Pituitary Neoplasms*/metabolism

  • Source: Neuro-oncology [Neuro Oncol] 2024 Nov 04; Vol. 26 (11), pp. 2010-2026.Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication

Record details

Read More Add to Saved list
×
Academic Journal

Inhibition of PERK-mediated unfolded protein response acts as a switch for reversal of residual senescence and as senolytic therapy in glioblastoma.

  • Authors : Ketkar M; Homi Bhabha National Institute, Training School Complex, Anushakti Nagar, Mumbai 400094, India.; Shilpee Dutt Laboratory, Tata Memorial Centre, Advanced Centre for Treatment, Research and Education in Cancer, Navi Mumbai 410210, India.

Subjects: Glioblastoma*/Glioblastoma*/Glioblastoma*/metabolism ; Glioblastoma*/Glioblastoma*/Glioblastoma*/pathology ; Glioblastoma*/Glioblastoma*/Glioblastoma*/drug therapy

  • Source: Neuro-oncology [Neuro Oncol] 2024 Nov 04; Vol. 26 (11), pp. 2027-2043.Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication

Record details

Read More Add to Saved list
×
Academic Journal

IL-13Rα2/TGF-β bispecific CAR-T cells counter TGF-β-mediated immune suppression and potentiate anti-tumor responses in glioblastoma.

  • Authors : Hou AJ; Department of Chemical and Biomolecular Engineering, University of California, Los Angeles, California, USA.; Shih RM

Subjects: Glioblastoma*/Glioblastoma*/Glioblastoma*/immunology ; Glioblastoma*/Glioblastoma*/Glioblastoma*/therapy ; Glioblastoma*/Glioblastoma*/Glioblastoma*/pathology

  • Source: Neuro-oncology [Neuro Oncol] 2024 Oct 03; Vol. 26 (10), pp. 1850-1866.Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication

Record details

Read More Add to Saved list
×
Academic Journal

An Orally Efficacious Thyrotropin Receptor Ligand Inhibits Growth and Metastatic Activity of Thyroid Cancers.

  • Authors : Sarkar R; National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD 20892, USA.; Bolel P

Subjects: Thyroid Neoplasms*/Thyroid Neoplasms*/Thyroid Neoplasms*/drug therapy ; Thyroid Neoplasms*/Thyroid Neoplasms*/Thyroid Neoplasms*/pathology ; Thyroid Neoplasms*/Thyroid Neoplasms*/Thyroid Neoplasms*/metabolism

  • Source: The Journal of clinical endocrinology and metabolism [J Clin Endocrinol Metab] 2024 Aug 13; Vol. 109 (9), pp. 2306-2316.Publisher: Oxford University Press Country of Publication: United States NLM ID: 0375362 Publication

Record details

Read More Add to Saved list
×
Academic Journal

ARF4-mediated retrograde trafficking as a driver of chemoresistance in glioblastoma.

  • Authors : Budhiraja S; Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Subjects: Glioblastoma*/Glioblastoma*/Glioblastoma*/metabolism ; Glioblastoma*/Glioblastoma*/Glioblastoma*/pathology ; Glioblastoma*/Glioblastoma*/Glioblastoma*/drug therapy

  • Source: Neuro-oncology [Neuro Oncol] 2024 Aug 05; Vol. 26 (8), pp. 1421-1437.Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication

Record details

Read More Add to Saved list
×
Academic Journal

The oncolytic adenovirus Delta-24-RGD in combination with ONC201 induces a potent antitumor response in pediatric high-grade and diffuse midline glioma models.

  • Authors : de la Nava D; Department of Pediatrics, Clínica Universidad de Navarra, Pamplona, Spain.; Solid Tumor Program, Center for the Applied Medical Research, Pamplona, Spain.

Subjects: Oncolytic Virotherapy*/Oncolytic Virotherapy*/Oncolytic Virotherapy*/methods ; Glioma*/Glioma*/Glioma*/therapy ; Glioma*/Glioma*/Glioma*/pathology

  • Source: Neuro-oncology [Neuro Oncol] 2024 Aug 05; Vol. 26 (8), pp. 1509-1525.Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication

Record details

Read More Add to Saved list
×
Academic Journal

Dual p38MAPK and MEK inhibition disrupts adaptive chemoresistance in mesenchymal glioblastoma to temozolomide.

  • Authors : Cheng HS; Lee Kong Chian School of Medicine, Nanyang Technological University Singapore, Singapore, Singapore.; School of Biological Sciences, Nanyang Technological University Singapore, Singapore, Singapore.

Subjects: Temozolomide*/Temozolomide*/Temozolomide*/pharmacology ; Glioblastoma*/Glioblastoma*/Glioblastoma*/drug therapy ; Glioblastoma*/Glioblastoma*/Glioblastoma*/pathology

  • Source: Neuro-oncology [Neuro Oncol] 2024 Jul 05; Vol. 26 (7), pp. 1247-1261.Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication

Record details

Read More Add to Saved list
×
Academic Journal

EGFR amplification and EGFRvIII predict and participate in TAT-Cx43266-283 antitumor response in preclinical glioblastoma models.

  • Authors : Álvarez-Vázquez A; Department of Biochemistry and Molecular Biology, Neuroscience Institute of Castilla y León (INCyL), Institute for Biomedical Research of Salamanca (IBSAL), University of Salamanca, Salamanca, Spain.; San-Segundo L

Subjects: Glioblastoma*/Glioblastoma*/Glioblastoma*/drug therapy ; Glioblastoma*/Glioblastoma*/Glioblastoma*/pathology ; Glioblastoma*/Glioblastoma*/Glioblastoma*/metabolism

  • Source: Neuro-oncology [Neuro Oncol] 2024 Jul 05; Vol. 26 (7), pp. 1230-1246.Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication

Record details

Read More Add to Saved list
×
Academic Journal

Abrogation of the G2/M checkpoint as a chemosensitization approach for alkylating agents.

  • Authors : Lang F; Neuro-Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA.; Cornwell JA

Subjects: Temozolomide*/Temozolomide*/Temozolomide*/pharmacology ; G2 Phase Cell Cycle Checkpoints*/G2 Phase Cell Cycle Checkpoints*/G2 Phase Cell Cycle Checkpoints*/drug effects ; Antineoplastic Agents, Alkylating*/Antineoplastic Agents, Alkylating*/Antineoplastic Agents, Alkylating*/pharmacology

  • Source: Neuro-oncology [Neuro Oncol] 2024 Jun 03; Vol. 26 (6), pp. 1083-1096.Publisher: Oxford University Press Country of Publication: England NLM ID: 100887420 Publication

Record details

Read More Add to Saved list
×
Academic Journal

Quantifying the activity profile of ASO and siRNA conjugates in glioblastoma xenograft tumors in vivo.

  • Authors : Sarli SL; RNA Therapeutics Institute, University of Massachusetts Chan Medical School, Worcester, MA, USA.; Fakih HH

Subjects: Glioblastoma*/Glioblastoma*/Glioblastoma*/genetics ; Glioblastoma*/Glioblastoma*/Glioblastoma*/metabolism ; Glioblastoma*/Glioblastoma*/Glioblastoma*/pathology

  • Source: Nucleic acids research [Nucleic Acids Res] 2024 May 22; Vol. 52 (9), pp. 4799-4817.Publisher: Oxford University Press Country of Publication: England NLM ID: 0411011 Publication Model:

Record details

Read More Add to Saved list
×
  • 1-10 of  623 results for ""Xenograft Model Antitumor Assays""